1)thrombin activatable fibrinolysis inhibitor (TAFI)凝血酶激活的纤溶抑制物(TAFI)
2)Thrombin-activatable fibrinolysis inhibitor凝血酶激活纤溶抑制物
3)Thrombin activatable fibrinolysis inhibitor凝血酶激活的纤溶抑制物
英文短句/例句
1.Studies on the Thrombin Activatable Fibrinolysis Inhibitor of Coronary Atherosclerotic Heart Disease;冠心病患者凝血酶激活的纤溶抑制物研究
2.Relationship between Thrombin Activated Fibrinolysis Inhibitor in Plasma and Vascular Complication in Type 2 Diabetes;血浆凝血酶激活的纤溶抑制物与2型糖尿病血管并发症的关系
3.Analysis of the Relationship Between Thrombin Activatable Fibrinolysis Inhibitor and Fibrinogen in Patients with Coronary Atherosclerotic Heart Disease冠心病患者凝血酶激活的纤溶抑制物与纤维蛋白原关系分析
4.Study of the Relativity between Thrombin-activatable Fibrinolysis Inhibtor and Stroke血浆凝血酶激活的纤溶抑制物与脑卒中的相关性研究
5.The Relationship between Thrombin-Activatable Fibrinolysis Inhibitor and Risk of Stroke血浆凝血酶激活的纤溶抑制物与脑卒中的相关性
6.The clinical study of plasma thrombin activatable fibrinolysis inhibitor in the patients with stroke脑卒中患者血浆凝血酶激活的纤溶抑制物的临床研究
7.A Study of Relation between Thrombin Activatable Fi Brinolysis Inhibition and Coronary Heart Disease.;凝血酶激活的纤溶抑制物与冠心病的相关性研究
8.Genetic polymorphism of thrombin-activatable fibrinolysis inhibitor(TAFI) associated with type 2 diabetes mellitus凝血酶激活的纤溶抑制物编码区基因多态性与2型糖尿病的关系
9.Study on the Association of the Gene Polymorphism of Thrombin Activatable Fibrinolysis Inhibitor with Coronary Atherosclerotic Heart Disease;冠心病患者凝血酶激活的纤溶抑制物及其编码区基因CPB2多态性的研究
10.Study on the the Association of Genetic Variations in Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Encoding Region and the Risk of Type 2 Diabetes Mellitus凝血酶激活的纤溶抑制物编码区基因CPB2多态性与2型糖尿病关系的研究
11.Effects of Thrombin-activable Fibrinolysis Inhibitor and Hirudin on Fibrinolysis;凝血酶激活的纤溶抑制剂与水蛭素对纤溶的影响
12.Study on the Levels of Thrombin Activable Fibrinolysis Inhibitor Active(TAFIa) in the Patients with Hemophilia血友病患者凝血酶激活的纤维蛋白溶解抑制物活性(TAFIa)的检测及其临床意义
13.Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究
14.Plasminogen Activator Inhibitor-1 and Cardiovascular Diseases纤溶酶原激活物抑制剂-1与心血管疾病
15.Activity of plasma tissue plasminogen activator and plasminogen activator inhibitor in patients with hypertensive disorder complicating pregnancy妊娠期高血压疾病患者血浆组织型纤溶酶原激活物及其抑制物的活性变化
16.The relation of plasma plasminogen activator inhibitor activity and coronary heart disease纤溶酶原激活抑制物活性与冠心病发病关系
17.The Varity and Mechnisim of the Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes with Hypertriglyceridemia;伴高甘油三酯血症的2型糖尿病纤溶酶原激活物抑制物-1水平变化及机制探讨
18.The Role of the Plasminogen Activator Inhibitor-1 in the Pathogenesis of Hepatic Fibrosis;纤溶酶原激活物抑制剂-1在肝纤维化发生中的作用
相关短句/例句
Thrombin-activatable fibrinolysis inhibitor凝血酶激活纤溶抑制物
3)Thrombin activatable fibrinolysis inhibitor凝血酶激活的纤溶抑制物
4)Thrombin Activable Fibrinolysis Inhibitor Active(TAFIa)凝血酶激活的纤维蛋白溶解抑制物活性
1.Study on the Levels of Thrombin Activable Fibrinolysis Inhibitor Active(TAFIa) in the Patients with Hemophilia血友病患者凝血酶激活的纤维蛋白溶解抑制物活性(TAFIa)的检测及其临床意义
5)TAFIa(TAFI activated)活化的凝血酶激活的纤溶抑制剂
6)thrombin-activable-fibrinolysis-inhibitor凝血酶激活的纤溶酶抑制剂
1.Fasting peripheral blood were obtained from all patients,and plasma thrombin-activable-fibrinolysis-inhibitor(TAFI)antigen and activity,plasmin-α2-antiplasmin(PAP),and plasmin-activator-inhibitor-1(PAI-1)were measured.取空腹外周血,用ELISA法检测血浆中凝血酶激活的纤溶酶抑制剂(TAFI)抗原、TAFI活性、纤溶酶-α2-抗纤溶酶复合物(PAP)和纤溶酶活化物抑制剂-1(PAI-1)。
延伸阅读
纤溶酶原激活剂分子式：CAS号：性质：是一组蛋白酶，使纤溶酶激活生成有活性的纤溶酶。它们主要包括：(1)组织纤溶酶激动剂(tPA)，一种丝氨酸蛋白酶，创伤或应激时从血管内皮释放入血，只有同纤维蛋白结合时才有激活纤溶酶原的活性；(2)尿激酶，对纤维蛋白选择性较低，是某些内皮细胞系合成、经外分泌管道(如肾小管)分泌，可能参与清除沉积在管道内的纤维蛋白；(3)链激酶，临床上用于裂解纤维蛋白，其选择性较差，可作用于液相中的纤溶酶原，也可作用于纤维蛋白血块中的纤溶酶原，链激酶不是蛋白酶，但与纤溶酶原结合成复合物后构象改变，显示蛋白水解酶活性。
